In a significant milestone for ophthalmology and autoimmune research, Ann Arbor-based biotechnology startup Sling Therapeutics has announced the successful closing of a $123 million Series C financing round. The capital injection provides the necessary runway for the company to push its lead candidate, linsitinib, into pivotal late-stage clinical trials. As the medical community grapples with the limitations of current injectable biologics for thyroid eye disease (TED), Sling’s oral small-molecule approach is being closely watched as a potential paradigm shift in patient care.
Main Facts: A New Frontier in TED Treatment
Thyroid eye disease, an inflammatory autoimmune condition often associated with Graves’ disease, manifests through painful swelling and protrusion of the eyes—a condition known as proptosis. For years, the treatment landscape has been dominated by intravenous or subcutaneous antibody-based therapies, such as Amgen’s Tepezza and the recently approved Lumvoa from Viridian Therapeutics.
Sling Therapeutics is positioning linsitinib as a disruptive alternative. By targeting the insulin-like growth factor-1 receptor (IGF-1R), which serves as a primary driver of inflammation in the orbital tissue, linsitinib mirrors the mechanism of action of existing biologics but delivers it in a twice-daily pill format.
The $123 million Series C round, led by Forbion with participation from TPG Life Sciences Innovations and Sectoral Asset Management, brings Sling’s total funding to $200 million since its 2022 inception. This robust financial backing underscores investor confidence in the company’s ability to navigate the complexities of late-stage clinical development and provide a more convenient, patient-friendly therapeutic option.
Chronology: From Oncology Re-purposing to Clinical Promise
The history of linsitinib is a testament to the power of strategic drug re-purposing. Originally developed by Astellas Pharma, the compound was previously subjected to extensive testing in over a dozen oncology indications. While it ultimately failed to gain traction in the highly competitive cancer market, those failures provided a treasure trove of safety and pharmacokinetic data that allowed Sling Therapeutics to accelerate its development timeline significantly.
- 2022: Sling Therapeutics officially launches, securing a licensing agreement with Astellas Pharma for linsitinib. This deal allows the startup to bypass early-stage discovery and move directly into mid-stage trials, leveraging existing safety data.
- 2024: The company advances its clinical program, establishing a rigorous testing regimen to prove that a small molecule can achieve efficacy comparable to large-molecule antibodies.
- January 2025: Sling announces positive topline results from its Phase 2b/3 LIDS clinical trial. The data shows a statistically significant 52% response rate after 24 weeks of treatment, with a notably favorable safety profile.
- February 2025: Sling announces the $123 million Series C funding round to support the launch of its global Phase 3 “Orbit” study.
Supporting Data: Why Small Molecules Matter
The primary challenge for previous IGF-1R inhibitors in the oncology space was their lack of specificity, leading to significant off-target toxicities. However, Ryan Zeidan, President and CEO of Sling Therapeutics, emphasizes that the clinical profile of linsitinib in TED is distinct.
"It’s a tricky target to hit," Zeidan noted in an interview with BioPharma Dive. By refining the delivery and focusing on the specific inflammatory pathways of the orbit, Sling believes it has mitigated the risks that plagued earlier iterations of the drug.
The Safety Advantage
Current biologics for TED have been associated with a range of concerning side effects, including hyperglycemia, hearing loss, and potential fertility issues. In contrast, the Phase 2b/3 LIDS trial results were encouraging:
- Efficacy: A 52% response rate at the 24-week mark.
- Safety Profile: Zero reported cases of drug-related hearing loss or tinnitus.
- Durability: Early data suggests that the small molecule’s effect may be more durable than traditional biologic infusions, potentially reducing the need for constant, medically supervised administration.
These data points are critical, as the current standard of care—often requiring hours-long infusions—places a significant burden on both patients and healthcare infrastructure.
Implications for the TED Market
The competitive landscape for TED is shifting rapidly. While companies like Immunovant and Argenx have faced hurdles in their pursuit of new treatments, the market remains hungry for innovation. The entry of players like Ethyreal Bio and Khartis into the space signals that the biology of the IGF-1R pathway is being intensely interrogated by the venture capital community.
Sling’s success, however, rests on its ability to prove that its "small molecule" designation is not just a marketing term, but a clinical advantage. If the Phase 3 "Orbit" trial confirms the efficacy seen in earlier stages, the convenience of an oral pill could disrupt the dominance of existing antibody treatments.
Expansion Opportunities
Beyond the current indication, CEO Ryan Zeidan has signaled that the company is exploring broader applications. Because linsitinib is a small molecule, it may be uniquely suited for:
- Earlier Intervention: Treating patients before the disease progresses to severe proptosis.
- Chronic TED: Addressing patients who have moved past the active inflammatory phase but still suffer from the physical disfigurement and discomfort of the condition.
"We have some really interesting commercial expansion opportunities and new patient indications that would benefit from this drug, that are unique to a small molecule oral therapeutic," Zeidan stated.
Official Responses and Investor Sentiment
The investment community has signaled a clear mandate for Sling to cross the finish line. Peter Bojo, a principal at TPG Life Sciences, summarized the sentiment following the Series C announcement: "Our continued investment into Sling reflects our confidence in the team’s execution and in linsitinib’s potential to meaningfully improve the treatment paradigm for TED patients."
For the patients, the implications are equally significant. If approved, linsitinib would represent a shift away from the "infusion center" model of care toward a "home-based" model, empowering patients to manage their condition with the same ease as a standard medication.
The Road Ahead: The "Orbit" Study
All eyes are now on the "Orbit" study. As a global, late-stage clinical trial, this study will be the definitive test for linsitinib. While the company has not provided a specific date for the release of topline data, the industry expects that the results will likely dictate the next five years of the TED market.
If the "Orbit" data holds steady against the high bar set by the LIDS trial, Sling Therapeutics will likely find itself as a prime target for acquisition by major pharmaceutical companies looking to bolster their immunology pipelines, or it may choose to go the route of a standalone commercial launch.
Regardless of the outcome, the company’s ability to leverage $200 million in private capital to challenge the status quo in autoimmune ophthalmology serves as a reminder of the biotech sector’s resilience. By focusing on precision and patient convenience, Sling is attempting to write a new chapter in the treatment of thyroid eye disease—one where the solution is as simple as a daily pill.
Summary of Strategic Advantages
- Convenience: Transition from IV infusions to twice-daily oral dosing.
- Safety: Reduction of systemic side effects, specifically avoiding hearing-related complications common in biologics.
- Efficiency: Accelerated path to market due to the successful repurposing of a legacy oncology asset.
- Market Position: A strong balance sheet with $200 million in total capital, providing the security needed to navigate the final regulatory hurdles of Phase 3 testing.
As the "Orbit" trial progresses, the biotech industry will continue to monitor Sling Therapeutics as a bellwether for the viability of oral small-molecule therapies in treating complex autoimmune conditions. For now, the Ann Arbor startup stands at the threshold of potentially redefining the standard of care for thousands of patients worldwide.
About the Author
